• Explore /
  • Poster
  • / IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

Abstract Video & Slides Poster

Authors

Heather Wakelee

Heather A. Wakelee

Stanford University Medical Center, Stanford, CA

Heather A. Wakelee , Nasser K. Altorki , Caicun Zhou , Tibor Csőszi , Ihor O. Vynnychenko , Oleksandr Goloborodko , Achim Rittmeyer , Martin Reck , Alex Martinez-Marti , Hirotsugu Kenmotsu , Yuh-Min Chen , Antonio Chella , Shunichi Sugawara , Chenqi Fu , Marcus Ballinger , Minu K Srivastava , Elizabeth Bennett , Barbara Jenifer Gitlitz , Enriqueta Felip , Yu Deng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Biologic Correlates

Clinical Trial Registration Number

NCT02486718

Citation

J Clin Oncol 42, 2024 (suppl 17; abstr LBA8035)

DOI

10.1200/JCO.2024.42.17_suppl.LBA8035

Abstract #

LBA8035

Poster Bd #

297

Abstract Disclosures

Similar Posters

First Author: Martin Reck

First Author: Heather A. Wakelee

First Author: Rita Migliorino

First Author: Thierry Landre